EICHOR
● Active Not Recruiting
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Condition: Neuroblastoma · Sponsor: Y-mAbs Therapeutics
About this study
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (20)
| Riley Hospital for Children | Indianapolis, Indiana, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| The Hospital for Sick Children | Toronto, Canada | — |
| Rigshospitalet | Copenhagen, Denmark | — |
| University Medical Center Hamburg-Eppendorf | Hamburg, Germany | — |
| Johannes Gutenberg-Universität | Mainz, Germany | — |
| University Hospital Regensburg | Regensburg, Germany | — |
| Hong Kong Children's Hospital | Hong Kong, Hong Kong | — |
| Queen Mary Hospital | Hong Kong, Hong Kong | — |
| Tata Memorial Centre | Mumbai, India | — |
| Giannina Gaslini Hospital | Genoa, Genoa, Italy | — |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Milan, Italy | — |
+ 8 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03363373